Label-free Assessment of Cardiomyocyte Activity

The Sony Cell Motion Imaging System SI8000

Figure 1: Label-free Monitoring of Cardiomyocyte Activity
The Sony SI8000 Cell Motion Imaging System supplies a high-speed video capture and analysis system for non-invasive monitoring of physiological activity.

Understanding and defining the effects of compounds on cardiac function is critically important in drug discovery and toxicity testing. CDI’s iCell Cardiomyocytes and iCell Cardiomyocytes2 provide a relevant and validated system for studying pharmacological effects on human cardiomyocyte activity.  Sony Instruments has launched the  SI8000 Cell Motion Imaging System for in vitro assessment of cardiomyocyte behavior (Figure 1).  As discussed in Hayakawa, et al. (2014), the motion activity of the cardiomyocytes is monitored to determine any drug-induced effects (Figure 2).

Additionally, CDI’s MyCell® products supply disease-specific cardiomyocytes through derivation from disease populations or genetic modification.

Together, these technologies provide a rapid, accurate, and robust label-free measurement of cardiomyocyte activity for use in developing newer, safer, and more effective pharmaceutical agents.

Contact CDI’s Technical Support team to learn more about iCell and MyCell products.

Refer to Sony Biotechnology Inc. to learn more about the SI8000 Cell Motion Imaging System.



Figure 2: Motion Analysis Enables Robust Detection of Drug-induced Effects
Cardiomyocyte movement is separated into vectors (upper images), which gives rise to a characteristic waveform that is used to assess drug effects (lower traces).


  1. Hayakawa T, Kunihiro T, et al. (2014) Image-based Evaluation of Contraction-relaxation Kinetics of Human-induced Pluripotent Stem Cell-derived Cardiomyocytes: Correlation and Complementarity with Extracellular Electrophysiology. J Mol Cell Cardiol 77:178-91.